<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00131404</url>
  </required_header>
  <id_info>
    <org_study_id>0364-015</org_study_id>
    <secondary_id>2005_031</secondary_id>
    <nct_id>NCT00131404</nct_id>
  </id_info>
  <brief_title>A Two Year Safety and Efficacy Study in Obese Patients (0364-015)(TERMINATED)</brief_title>
  <official_title>A 2-Year Study to Assess the Efficacy, Safety, and Tolerability of Taranabant in Obese Patients Followed by a 1-Year Extension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      A study to determine the safety and efficacy of an investigational drug in patients with
      obesity plus extension.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The overall profile does not support development for obesity
  </why_stopped>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decreases body weight; safety and tolerability</measure>
    <time_frame>156 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decreases waist circumference, the proportion of patients with metabolic syndrome, triglycerides, non-HDL-C, LDL-C, fasting insulin, FPG; increases HDL-C, insulin sensitivity</measure>
    <time_frame>156 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">2400</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Phase A/B: Arm 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Phase A: Arm 1: MK0364 Pbo capsule once daily.
Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 1: MK0364 Pbo capsule once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase A/B: Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase A: Arm 2: MK0364 2 mg capsule once daily.
Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 2: MK0364 2 mg capsule once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase A/B: Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase A: Arm 3: MK0364 4 mg capsule once daily.
Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 3:
MK0364 4 mg capsule once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase A/B: Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase A: Arm 4: MK0364 6 mg capsule once daily.
Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 4:
MK0364 6 mg capsule once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase A/B: Arm 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase A: Arm 5: MK0364 6 mg capsule once daily. 52 week treatment period. Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 5: MK0364 6 mg capsule once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>taranabant</intervention_name>
    <description>taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule once daily. 52 week treatment period.</description>
    <arm_group_label>Phase A/B: Arm 2</arm_group_label>
    <arm_group_label>Phase A/B: Arm 3</arm_group_label>
    <arm_group_label>Phase A/B: Arm 4</arm_group_label>
    <arm_group_label>Phase A/B: Arm 5</arm_group_label>
    <other_name>MK0364</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>Placebo capsule once daily. 52 week treatment period.</description>
    <arm_group_label>Phase A/B: Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Obese patients with a body mass index between 30 kg/m2 and 43 kg/m2, inclusive (BMI
             between 27 kg/m2 and 43 kg/m2, inclusive for those with obesity-related comorbidities
             including hypertension, dyslipidemia, and sleep apnea

        Exclusion Criteria:

          -  Patients with serious or unstable current or past medical conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Peru</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Aronne LJ, Tonstad S, Moreno M, Gantz I, Erondu N, Suryawanshi S, Molony C, Sieberts S, Nayee J, Meehan AG, Shapiro D, Heymsfield SB, Kaufman KD, Amatruda JM. A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study. Int J Obes (Lond). 2010 May;34(5):919-35. doi: 10.1038/ijo.2010.21. Epub 2010 Feb 16.</citation>
    <PMID>20157323</PMID>
  </results_reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2005</study_first_submitted>
  <study_first_submitted_qc>August 17, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2005</study_first_posted>
  <last_update_submitted>February 4, 2015</last_update_submitted>
  <last_update_submitted_qc>February 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

